ZA959653B - Derivatives of BDNF and NT-3. - Google Patents

Derivatives of BDNF and NT-3.

Info

Publication number
ZA959653B
ZA959653B ZA9509653A ZA959653A ZA959653B ZA 959653 B ZA959653 B ZA 959653B ZA 9509653 A ZA9509653 A ZA 9509653A ZA 959653 A ZA959653 A ZA 959653A ZA 959653 B ZA959653 B ZA 959653B
Authority
ZA
South Africa
Prior art keywords
derivatives
bdnf
polypeptides
instance
attachment
Prior art date
Application number
ZA9509653A
Other languages
English (en)
Inventor
Olaf B Kinstler
Qiao Yan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of ZA959653B publication Critical patent/ZA959653B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/839—Nerves; brain
ZA9509653A 1994-11-14 1995-11-14 Derivatives of BDNF and NT-3. ZA959653B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/340,131 US5770577A (en) 1994-11-14 1994-11-14 BDNF and NT-3 polypeptides selectively linked to polyethylene glycol

Publications (1)

Publication Number Publication Date
ZA959653B true ZA959653B (en) 1997-08-26

Family

ID=23332020

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9509653A ZA959653B (en) 1994-11-14 1995-11-14 Derivatives of BDNF and NT-3.

Country Status (22)

Country Link
US (1) US5770577A (zh)
EP (1) EP0792288B1 (zh)
JP (1) JPH10508853A (zh)
KR (1) KR100253762B1 (zh)
CN (1) CN1173183A (zh)
AT (1) ATE175973T1 (zh)
AU (1) AU694589B2 (zh)
CA (1) CA2204640C (zh)
CZ (1) CZ137597A3 (zh)
DE (1) DE69507507T2 (zh)
DK (1) DK0792288T3 (zh)
ES (1) ES2126331T3 (zh)
GR (1) GR3029790T3 (zh)
HU (1) HUT77747A (zh)
IL (1) IL115965A (zh)
MX (1) MX9703362A (zh)
NO (1) NO972176L (zh)
NZ (1) NZ296452A (zh)
RU (1) RU2136694C1 (zh)
SK (1) SK283083B6 (zh)
WO (1) WO1996015146A1 (zh)
ZA (1) ZA959653B (zh)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JPH10212241A (ja) * 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Ｂｄｎｆを安定に含有する製剤
AU720232B2 (en) 1996-07-19 2000-05-25 Amgen, Inc. Analogs of cationic proteins
WO2000024415A2 (en) * 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
US6656474B1 (en) * 1999-01-15 2003-12-02 Regeneron Pharmaceuticals, Inc. Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
US6800607B2 (en) * 2000-02-29 2004-10-05 Ltt Bio-Pharma Co., Ltd. Modified BDNF
US7514239B2 (en) * 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
SI1355936T1 (sl) * 2001-02-01 2007-12-31 Biogen Idec Inc Polimerni konjugati neublastina in postopki njihove uporabe
PL362414A1 (en) 2001-02-19 2004-11-02 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
EA008866B1 (ru) * 2002-12-26 2007-08-31 Маунтин Вью Фамэсьютикэлс, Инк. ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
PL396711A1 (pl) * 2002-12-26 2011-12-19 Mountain View Pharmaceuticals, Inc. Koniugaty polimerów z cytokinami, chemokinami, czynnikami wzrostu, hormonami polipeptydowymi i ich antagonistami, kompozycja farmaceutyczna i sposób zapobiegania, diagnozowania lub leczenia
NZ541921A (en) * 2003-01-31 2010-01-29 Biogen Idec Inc Polymer conjugates of mutated neublastin
SI2248899T1 (sl) 2003-03-19 2015-07-31 Biogen Ma Inc. Vezavni protein receptorja Nogo
ES2479942T3 (es) 2003-04-18 2014-07-25 Biogen Idec Ma Inc. Neublastina glucosilada conjugada con polímero
EP1720564A1 (en) * 2004-02-20 2006-11-15 Rinat Neuroscience Corp. Methods of treating obesity or diabetes using nt-4/5
EP2474317A1 (en) 2004-06-24 2012-07-11 Biogen Idec MA Inc. Treatment of conditions involving demyelination
EP2238983B1 (en) * 2004-08-19 2014-07-23 Biogen Idec MA Inc. Neublastin variants
EP1784203B1 (en) 2004-08-19 2010-06-30 Biogen Idec MA Inc. Refolding transforming growth factor beta family proteins
US7750122B2 (en) 2005-06-06 2010-07-06 Wyeth Llc Anti-TrkB monoclonal antibodies and uses thereof
WO2007008547A2 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
CA2637707A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Methods for treating obesity by administering a trkb antagonist
AU2007210862A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corp. Methods for treating unwanted weight loss or eating disorders by administering a trkB agonist
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
WO2007103182A2 (en) * 2006-03-01 2007-09-13 Biogen Idec Ma Inc. Compostions and methods for administering gdnf ligand family proteins
AU2007249709A1 (en) * 2006-05-15 2007-11-22 Viral Logic Systems Technology Corp. CD47 related compositions and methods for treating immunological diseases and disorders
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
US20100086997A1 (en) * 2006-12-20 2010-04-08 Rinat Enuroscience Corp TrkB Agonists for Treating Autoimmune Disorders
EP2142205B1 (en) 2007-05-01 2014-04-02 Biogen Idec MA Inc. Neublastin peptides for use in increasing vascularisation in tissue with impaired blood flow
EP2205634A2 (en) * 2007-08-08 2010-07-14 Biogen Idec MA, Inc. Anti-neublastin antibodies and uses thereof
US20100297121A1 (en) * 2007-10-11 2010-11-25 Biogen Idec Ma Inc. Methods for Treating Pressure Induced Optic Neuropathy, Preventing Neuronal Degeneration and Promoting Neuronal Cell Survival Via Administration of LINGO-1 Antagonists and TrkB Agonists
CA2702630C (en) * 2007-11-08 2017-11-21 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
US8058406B2 (en) 2008-07-09 2011-11-15 Biogen Idec Ma Inc. Composition comprising antibodies to LINGO or fragments thereof
MX2013000250A (es) 2010-07-02 2013-10-28 Angiochem Inc Polipeptidos cortos y que contienen d-aminoacido para conjugados terapeuticos y usos de los mismos.
CA2873623C (en) 2012-05-14 2021-11-09 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
CN102964442B (zh) * 2012-11-19 2015-04-29 未名生物医药有限公司 一种聚乙二醇同神经生长因子结合物的制备方法
MX2017009038A (es) 2015-01-08 2017-10-25 Biogen Ma Inc Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
CN111514279B (zh) * 2020-06-16 2023-07-18 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 神经营养因子3在制备治疗男性性腺功能减退症的药物中的应用
CN115025723A (zh) * 2022-05-10 2022-09-09 吉林大学 经神经生长因子及多巴胺改良的peg-plga微球

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US5169762A (en) * 1983-03-03 1992-12-08 Genentech, Inc. Human nerve growth factor by recombinant technology
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
EP0401384B1 (en) * 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
GR1000980B (el) * 1989-08-30 1993-03-31 Max Planck Gesellschaft Νευροτροφινη-3,ενας νεος neυροτροφικος παραγοντας που σχετιζεται με τον παραγοντα αναπτυξης νευρων και τον νευροτροφικο παραγοντα που προερχεται απο τον εγκεφαλο.
US5180820A (en) * 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
AU654302B2 (en) * 1990-09-25 1994-11-03 Genentech Inc. Novel neurothrophic factor
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5389529A (en) * 1991-06-12 1995-02-14 Regeneron Pharmaceuticals, Inc. Modified lamβ signal sequence and processes for producing recombinant neurotrophins
NZ244778A (en) * 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
US5260308A (en) * 1991-11-06 1993-11-09 Mayo Foundation For Medical Education And Research Method to increase permeability of the blood-nerve/brain barriers to proteins
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders

Also Published As

Publication number Publication date
CA2204640C (en) 2001-01-09
ATE175973T1 (de) 1999-02-15
CZ137597A3 (cs) 1998-10-14
DK0792288T3 (da) 1999-09-13
DE69507507T2 (de) 1999-05-27
NO972176L (no) 1997-07-14
CN1173183A (zh) 1998-02-11
MX9703362A (es) 1997-08-30
SK57197A3 (en) 1999-02-11
NZ296452A (en) 1999-01-28
DE69507507D1 (de) 1999-03-04
AU4107196A (en) 1996-06-06
GR3029790T3 (en) 1999-06-30
HUT77747A (hu) 1998-07-28
SK283083B6 (sk) 2003-02-04
EP0792288B1 (en) 1999-01-20
RU2136694C1 (ru) 1999-09-10
CA2204640A1 (en) 1996-05-23
US5770577A (en) 1998-06-23
AU694589B2 (en) 1998-07-23
IL115965A0 (en) 1996-01-31
IL115965A (en) 2001-01-28
ES2126331T3 (es) 1999-03-16
NO972176D0 (no) 1997-05-12
KR100253762B1 (ko) 2000-05-01
EP0792288A1 (en) 1997-09-03
JPH10508853A (ja) 1998-09-02
WO1996015146A1 (en) 1996-05-23

Similar Documents

Publication Publication Date Title
ZA959653B (en) Derivatives of BDNF and NT-3.
AU7321498A (en) Bit-interleaved rate16/17 modulation code with three-way byte-interleaved ECC
EP0600470A3 (en) Bipolar membrane.
EP0648239A4 (en) BIOCOMPATIBLE POLYMERIC CONJUGATES.
AU6158390A (en) Very high molecular weight polyethylene
AU7649191A (en) 1-h-3-aryl-pyrrolidine-2,4-dione derivatives
HU9700126D0 (en) 2-oxo- and 2-thio-1,2-dihydroquinolinyl-oxazotidinone derivatives
AU1782495A (en) Encapsulation with water soluble polymer
AU6878894A (en) 1-benzenesulfonyl-1,3-dihydro-2H-benzimidazol-2-one derivatives
AU2307895A (en) Collagen preparation for the controlled release of active substances
AU1316995A (en) Indole derivatives as anti-estrogens
GB2285806B (en) Alkali-treated bagasse,and its preparation and uses
EP0662087A4 (en) NEUROTROPHIC FACTOR DERIVED FROM PIGMENT RETINAL EPITHELIUM.
ZA979944B (en) Heat-sealing polymer films.
EP0396394A3 (en) Sterilisable lubricant
IS4190A (is) Hliðstæð aðferð til framleiðslu á 1,5 bensódíasepín afleiðum
AU630553B2 (en) Light colored, aromatic-modified piperylene resins
AU666351B2 (en) Water soluble polymers
AU697041B2 (en) Mannich base derivatives, and the production and uses thereof
AU1357597A (en) Substituted ethyl alpha,alpha - diarylmethyl ether derivatives
ZA943455B (en) Tricyclic cefem sulphones.
AU4723897A (en) 1,4-benzoquinone derivatives
PL270277A1 (en) Pumping station system,especially for maintaining constant pressure in zonal municipal water-main networks
EP0621623A3 (en) Double-based low pressure discharge lamp.
ZA971518B (en) Pharmaceutical composition for immunomodulation.